2. Search Result
Search Result
Results for "

JNK inhibitor

" in MedChemExpress (MCE) Product Catalog:

116

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

13

Peptides

21

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15617
    JNK-IN-7
    4 Publications Verification

    JNK inhibitor

    		 JNK Cancer
    JNK-IN-7 is a potent JNK inhibitor with IC50 of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, respectively.
    JNK-IN-7
  • HY-13319
    JNK-IN-8
    30+ Cited Publications

    JNK inhibitor XVI

    		 JNK Cancer
    JNK-IN-8 (JNK Inhibitor XVI) is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively .
    JNK-IN-8
  • HY-107598
    JNK Inhibitor VIII
    2 Publications Verification

    TCS JNK 6o

    		 JNK Cancer
    JNK Inhibitor VIII (TCS JNK 6o) is a c-Jun N-terminal kinases (JNK-1, -2, and -3) inhibitor with Ki values of 2 nM, 4 nM, 52 nM, respectively, and has IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively .
    <em>JNK</em> <em>Inhibitor</em> VIII
  • HY-15881
    TCS JNK 5a
    1 Publications Verification

    JNK inhibitor IX

    		 JNK Apoptosis Cancer
    TCS JNK 5a is a potent JNK3 inhibitor with a pIC50 of 6.7. TCS JNK 5a also inhibits JNK2 with a pIC50 of 6.5.
    TCS JNK 5a
  • HY-13319G
    JNK-IN-8

    JNK inhibitor XVI

    		 JNK Cancer
    JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively .
    JNK-IN-8
  • HY-112402
    SP 600125, negative control

    JNK inhibitor II, negative control

    		 Others Cancer
    SP 600125, negative control (SPM1) is an alkyl derivative of pyrazoloanthrone, which can be used as a negative control for SP600125 (HY-12041) .
    SP 600125, negative control
  • HY-149279
    JNK3 inhibitor-7

    		JNK Neurological Disease
    JNK3 inhibitor-7 is a potent, orally active and cross the blood-brain barrier JNK3 inhibitor with IC50 values of 53, 973, 1039 nM for JNK3, JNK2, JNK1, respectively. JNK3 inhibitor-7 shows significant neuroprotective effects. JNK3 inhibitor-7 has the potential for the research of Alzheimer’s disease (AD) .
    <em>JNK</em>3 <em>inhibitor</em>-7
  • HY-149280
    JNK3 inhibitor-8

    		JNK Neurological Disease
    JNK3 inhibitor-8 is a potent, delective, orally active and cross the blood-brain barrier JNK3 inhibitor with IC50 values of 21, 2203, >10000 nM for JNK3, JNK2, JNK1, respectively. JNK3 inhibitor-8 shows significant neuroprotective effects. JNK3 inhibitor-8 has the potential for the research of Alzheimer’s disease (AD) .
    <em>JNK</em>3 <em>inhibitor</em>-8
  • HY-150552
    JNK3 inhibitor-2

    		JNK Discoidin Domain Receptor Inflammation/Immunology Cancer
    JNK3 inhibitor-2 is a potent and selective JNK3 inhibitor with IC50 values of >100, >100, 0.25 µM for JNK1, JNK2, JNK3, respectively. JNK3 inhibitor-2 shows DDR1 and EGFR (T790M, L858R) inhibition .
    <em>JNK</em>3 <em>inhibitor</em>-2
  • HY-151928
    JNK3 inhibitor-3

    		JNK Neurological Disease
    JNK3 inhibitor-3 (compound 15g) is a selective, BBB permeable and orally active c-Jun N-terminal kinase 3 (JNK3) inhibitor. JNK3 inhibitor-3 has inhibitory activities to JNK1, JNK2 and JNK3 with IC50 values of 147.8, 44.0 and 4.1 nM, respectively. JNK3 inhibitor-3 significantly improves the memory in mouse dementia model. JNK3 inhibitor-3 can be used for the research of Alzheimer’s disease .
    <em>JNK</em>3 <em>inhibitor</em>-3
  • HY-139624
    JNK3 inhibitor-1

    		JNK Others
    JNK3 inhibitor-1 is a potent and selective JNK3 inhibitor (IC50 = 0.005 μM). JNK3 inhibitor-1 is orally bioavailable and brain penetrant.
    <em>JNK</em>3 <em>inhibitor</em>-1
  • HY-151962
    JNK3 inhibitor-5

    		JNK Apoptosis GSK-3 p38 MAPK Neurological Disease
    JNK3 inhibitor-5 (Compound 22b) is a potent and selective JNK3 inhibitor with an IC50 of 0.379 nM. JNK3 inhibitor-5 effectively protects the neuronal cells against amyloid beta-induced apoptosis. JNK3 inhibitor-5 has a high cell permeability and is predicted as BBB permeable .
    <em>JNK</em>3 <em>inhibitor</em>-5
  • HY-149268
    JNK3 inhibitor-6

    		JNK Neurological Disease
    JNK3 inhibitor-6 (Compound A53) is a selective JNK3 Inhibitor (IC50=78 nM). JNK3 inhibitor-6 has neuroprotective effect, and can used for research of neurodegenerative diseases .
    <em>JNK</em>3 <em>inhibitor</em>-6
  • HY-151929
    JNK3 inhibitor-4

    		JNK Neurological Disease
    JNK3 inhibitor-4 is a potent inhibitor of JNK3 (IC50=1.0 nM) based on 2-aryl-1-pyrimidinyl-1H-imidazole-5-yl acetonitrile. JNK3 inhibitor-4 shows excellent selectivity over other protein kinases including isoforms JNK1 (IC50=143.9 nM) and JNK2 (IC50=298.2 nM) . JNK3 inhibitor-4 has neuroprotective effect and predicated blood-brain barrier permeability .
    <em>JNK</em>3 <em>inhibitor</em>-4
  • HY-14411
    JNK-1-IN-1

    		JNK Cancer
    JNK-1-IN-1 is a JNK-1 inhibitor. JNK-1-IN-1 also inhibits MKK7 with an IC50 of 7.8μM. JNK-1-IN-1 bind to MKK7cp and acts as an inhibitor of JNK-1 .
    JNK-1-IN-1
  • HY-155593
    JNK-1-IN-2

    		JNK Inflammation/Immunology
    JNK-1-IN-2 (Compound c6) is a JNK-1 inhibitor (IC50: 33.5 nM). JNK-1-IN-2 also inhibits JNK-2 and JNK-3 with IC50s of 112.9 nM and 33.2 nM. JNK-1-IN-2 inhibits the phosphorylation of c-Jun. JNK-1-IN-2 reverses lung impairment. JNK-1-IN-2 can be used for research of pulmonary fibrosis .
    JNK-1-IN-2
  • HY-14761
    Bentamapimod
    5+ Cited Publications

    AS 602801

    		 JNK Cancer
    Bentamapimod (AS 602801) is an ATP-competitive JNK inhibitor with IC50 of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively.
    Bentamapimod
  • HY-P10140
    JNK-IN-15, Cell-Permeable

    		JNK Cancer
    JNK-IN-15, Cell-Permeable (JNK inhibitor III) is an inhibitor of JNK. JNK-IN-15, Cell-Permeable can used in study age-related neurodegenerative diseasev .
    JNK-IN-15, Cell-Permeable
  • HY-149485
    JNK2-IN-1

    		JNK Inflammation/Immunology
    JNK2-IN-1 (Compound J27) is a JNK2 inhibitor (Kds: 79.2 μM). JNK2-IN-1 has anti-inflammatory activity. JNK2-IN-1 decreases the release of TNF-α and IL-6 through inhibiting the activation of NF-κB/MAPK pathway. JNK2-IN-1 alleviates the symptoms of LPS-induced acute lung injury (ALI) and sepsis .
    JNK2-IN-1
  • HY-149930
    YL5084

    		JNK Apoptosis Cancer
    YL5084, a covalent JNK inhibitor, exhibits selectivity for JNK2 and JNK3 over JNK1 with IC50s of 70 nM, 84 nM and 2173 nM, respectively. YL5084 exhibits JNK2-independent antiproliferative effects and induces apoptosis in a JNK2-independent manner .
    YL5084
  • HY-155077
    JNK-IN-12

    		JNK Cancer
    JNK-IN-12 (compound P2) is a mitochondrial-targeted JNK inhibitor (IC50=66.3 nM), consisting of a mitochondrial-specific cell-penetrating peptide and a specific inhibitor of JNK, SP600125 (HY-12041). JNK-IN-12 doesn't inhibit nuclear JNK signaling, but does inhibit mitochondrial JNK phosphorylation. JNK-IN-12 helps to improve the Parkinson's disease (PD) both in vitro and in vivo .
    JNK-IN-12
  • HY-77009
    JNK-IN-13

    		JNK Cancer
    JNK-IN-13 (compound 1) is a potent and selective JNK inhibitor with IC50s of 290 nM and 500 nM for JNK3 and JNK2, respectively .
    JNK-IN-13
  • HY-13275
    IRAK inhibitor 1

    		IRAK Inflammation/Immunology
    IRAK inhibitor 1 is a potent IRAK-4 inhibitor with IC50 of 216 nM, is poorly active against JNK-1 and JNK-2 with IC50 of 3.801 μM, and >10 μM, respectively.
    IRAK <em>inhibitor</em> 1
  • HY-150053
    JNK-IN-11

    		JNK Neurological Disease
    JNK-IN-11 (compound 1) is a potent JNK inhibitor with an IC50 value of 2.2, 21.4, 1.8 µM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease .
    JNK-IN-11
  • HY-P2246
    JTP10-△-TATi TFA

    		JNK Cancer
    JTP10-△-TATi TFA is a selective JNK2 peptide inhibitor, with an IC50 of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .
    JTP10-△-TATi TFA
  • HY-P10141
    JNK-IN-15, Cell-Permeable, Negative Control

    		JNK Cancer
    JNK-IN-15, Cell-Permeable, Negative Control is a negative control of JNK-IN-15, Cell-Permeable (HY-P10140). JNK-IN-15, Cell-Permeable is an inhibitor of JNK .
    JNK-IN-15, Cell-Permeable, Negative Control
  • HY-156182
    JNK-IN-14

    		JNK Cytochrome P450 Cancer
    JNK-IN-14 is a potent JNK inhibitor with IC50 values of 1.81, 12.7 and 10.5 nM for JNK1, JNK2 and JNK3, respectively. JNK-IN-14 induces early-stage apoptosis. JNK-IN-14 shows cell population arrest at the G2/M phase and slightly inhibits beclin-1 production at K562 leukemia cells relative to SP600125 (HY-12041), showing higher inhibitory ability.
    JNK-IN-14
  • HY-P2247
    JTP10-△-R9 TFA

    		JNK Cancer
    JTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC50 of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3 .
    JTP10-△-R9 TFA
  • HY-107600
    IQ-3
    1 Publications Verification

    		 JNK Inflammation/Immunology
    IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits Kd values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively .
    IQ-3
  • HY-N7394A
    (-)-Zuonin A
    1 Publications Verification

    D-Epigalbacin

    		 JNK Cancer
    (-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC50s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively .
    (-)-Zuonin A
  • HY-12041
    SP600125
    Maximum Cited Publications
    411 Publications Verification

    		 JNK Autophagy Apoptosis Ferroptosis Cancer
    SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
    SP600125
  • HY-147836
    Akt/NF-κB/JNK-IN-1

    		Akt NF-κB JNK TNF Receptor COX Inflammation/Immunology
    Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signaling pathways. Akt/NF-κB/JNK-IN-1 inhibits nitric oxide production with an IC50 of 3.15 μM. Akt/NF-κB/JNK-IN-1 shows anti-inflammatory activities .
    Akt/NF-κB/JNK-IN-1
  • HY-144761
    TOPK-p38/JNK-IN-1

    		JNK Cancer
    TOPK-p38/JNK-IN-1 (Compound B12) is an orally active TOPK-p38/JNK signaling pathway inhibitor with the IC50 value of 2.14 µM for NO production. TOPK-p38/JNK-IN-1 shows anti-inflammatory activities. TOPK-p38/JNK-IN-1 also inhibits phosphorylate downstream related proteins and avoids degradation of TOPK .
    TOPK-p38/JNK-IN-1
  • HY-10366
    BI-78D3
    1 Publications Verification

    		 JNK Metabolic Disease Cancer
    BI-78D3 functions as a substrate competitive inhibitor of JNK, inhibit the JNK kinase activity (IC50=280 nM).
    BI-78D3
  • HY-15495
    Tanzisertib
    5+ Cited Publications

    CC-930

    		 JNK Inflammation/Immunology
    Tanzisertib (CC-930) is a potent JNK1/2/3 inhibitor with IC50s of 61/7/6 nM, respectively.
    Tanzisertib
  • HY-162332
    EGFR-PK/JNK-2-IN-1

    		Apoptosis EGFR JNK Cancer
    EGFR-PK/JNK-2-IN-1 (Compound 6c) is a dual inhibitor of EGFR-PK and JNK-2 with IC50s of 2.7 and 3.0 μM, respectively. EGFR-PK/JNK-2-IN-1 can induce apoptosis and induce cell cycle arrest at different cell phases. EGFR-PK/JNK-2-IN-1 can be used for the research of cancer .
    EGFR-PK/JNK-2-IN-1
  • HY-107597
    Halicin
    1 Publications Verification

    SU3327

    		 JNK Metabolic Disease Inflammation/Immunology
    Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt kinase .
    Halicin
  • HY-100233
    IQ-1S free acid
    1 Publications Verification

    		 JNK Inflammation/Immunology Cancer
    IQ-1S free acid is a prospective inhibitor of NF-κB/activating protein 1 (AP-1) activity with an IC50 of 2.3±0.41 μM. IQ-1S free acid has binding affinity (Kd values) in the nanomolar range for all three JNKs with Kds of 100 nM, 240 nM, and 360 nM for JNK3, JNK1, and JNK2, respectively.
    IQ-1S free acid
  • HY-N0773
    Isovitexin
    3 Publications Verification

    Saponaretin; Homovitexin

    		 JNK NF-κB Inflammation/Immunology
    Isovitexin is a flavonoid isolated from passion flower, Cannabis and, and the palm, possesses anti-inflammatory and anti-oxidant activities; Isovitexin acts like a JNK1/2 inhibitor and inhibits the activation of NF-κB.
    Isovitexin
  • HY-12862
    Mps1-IN-7

    		Mps1 Cancer
    Mps1-IN-7 is a potent MPS1 inhibitor (IC50 of 0.020 μM) over JNK1 and JNK2 (JNK1 IC50= 0.11 μM, JNK2 IC50=0.22 μM). Mps1-IN-7 inhibit SW620, CAL51, Miapaca-2, RMG1 cell growth with GI50 values of 0.065, 0.068, 0.25, and 0.110 μM,respectively .
    Mps1-IN-7
  • HY-138304
    CC-90001
    1 Publications Verification

    		 JNK Inflammation/Immunology
    CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis .
    CC-90001
  • HY-18982
    Anisomycin
    55+ Cited Publications

    Flagecidin; Wuningmeisu C

    		 DNA/RNA Synthesis JNK Bacterial Apoptosis Antibiotic Parasite Infection Cancer
    Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system . Anisomycin is a JNK activator, which increases phospho-JNK . Anisomycin is a bacterial antibiotic .
    Anisomycin
  • HY-108646
    SX 011

    		p38 MAPK JNK Inflammation/Immunology
    SX 011 is a p38 inhibitor with IC50s of 9 nM and 90 nM against p38α and p38β, respectively. SX 011 also inhibits JNK-2 with an IC50 of 100 nM. SX-011 is orally bioavailable .
    SX 011
  • HY-15737
    DB07268
    4 Publications Verification

    		 JNK Cancer
    DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM.
    DB07268
  • HY-12829
    SR-3306

    		JNK Neurological Disease
    SR-3306 is a selective, potent, highly brain penetrant JNK inhibitor.
    SR-3306
  • HY-P0069A
    L-JNKI-1
    2 Publications Verification

    		 JNK Neurological Disease
    L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.
    L-JNKI-1
  • HY-125838
    J30-8

    		JNK Neurological Disease
    J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases .
    J30-8
  • HY-139254
    Indirubin-3′-oxime

    IDR3O; I3O

    		 CDK GSK-3 JNK Neurological Disease
    Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes .
    Indirubin-3′-oxime
  • HY-13022
    CC-401 hydrochloride
    5 Publications Verification

    CC401 HCl

    		 JNK Cancer
    CC-401 hydrochloride is a potent inhibitor of all three forms of JNK with Ki of 25 to 50 nM.
    CC-401 hydrochloride
  • HY-13022A
    CC-401

    		JNK Cancer
    CC-401 is a potent inhibitor of all three forms of JNK with Ki of 25 to 50 nM.
    CC-401

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: